← All United Therapeutics CORP filings

United Therapeutics CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
UTHR
United Therapeutics CORP
10-K: United Therapeutics Reports Strong 2025 Revenue Growth
United Therapeutics Corporation reported an 11% increase in total revenues for 2025, driven by robust sales of Tyvaso DPI and Orenitram, alongside significant advancements in its organ manufacturing pipeline.
NASDAQ
UTHR
United Therapeutics CORP
10-K: United Therapeutics Reports Strong 2024 Results, Driven by Tyvaso DPI Growth
United Therapeutics' 2024 annual report highlights significant revenue growth, particularly driven by Tyvaso DPI, and advancements in manufactured organs and organ alternatives.
NASDAQ
UTHR
United Therapeutics CORP
10-K: United Therapeutics Details Stock Structure and Public Benefit Goals in SEC Filing
United Therapeutics outlines its common stock details, public benefit corporation status, and various corporate governance policies in a recent SEC filing.